Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a pow... Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 98 | 0.0001 | CS |
| 12 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 1276 | 2.803E-5 | CS |
| 26 | 9.9E-5 | 9900 | 1.0E-6 | 0.0002 | 1.0E-6 | 35791 | 7.61E-5 | CS |
| 52 | 0 | 0 | 0.0001 | 0.01 | 1.0E-6 | 40488 | 8.643E-5 | CS |
| 156 | -0.0111 | -99.1071428571 | 0.0112 | 0.0278 | 1.0E-6 | 115071 | 0.01201939 | CS |
| 260 | -0.0998 | -99.8998998999 | 0.0999 | 0.12 | 1.0E-6 | 255971 | 0.02252887 | CS |
| Nessuna Discussione Trovata |
| Crea Discussione |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
